Drug-releasing bone void fillers that prevent orthopedic infection and promote bone healing.
Elute, Inc. aims to be the leader in the development and commercialization of a new class of patented and patent pending drug eluting devices designed for controlled and sustained release of drugs aimed at preventing and treating bone infections. Elute’s products provide a clinically relevant delivery of antibiotics and other therapeutic agents directly into surgical sites of patients undergoing orthopedic procedures. Elute's first product candidate, ElutiBoneTM, has shown in in-vitro tests the controlled release of certain antibiotics in a therapeutic range for a 7-8 week period. Furthermore, animal studies confirm that ElutiBone eliminates pathogens in vivo, while preventing infection in large and small animal peri-operative infection models while simultaneously enhancing bone formation.